Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Dapagliflozin on Renal Morphology and Perfusion After Kidney Transplantation
NCT06560801Phase 4Recruiting
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Jul 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in chronic kidney disease (CKD), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started Jul 2023; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06560801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560801.